Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)

NCT01550224 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia With 11q23-abnormality in Relapse

Interventions

DRUG: Temozolomide
DRUG: Vorinostat

Sponsor

Steven E. Coutre

Collaborators

[object Object]